Gold prices bounce off 3-week lows; demand likely longer term
Investing.com -- Biogen Inc. reported fourth-quarter earnings that beat analyst expectations, but its shares fell 3.2% premarket as the company’s guidance for 2025 disappointed.
The biotechnology firm posted adjusted earnings per share of $3.44 for Q4 2024, surpassing the consensus estimate of $3.41. Revenue came in at $2.5 billion, above analysts’ projections of $2.41 billion and representing a 3% year-over-year increase.
The company forecasts full-year 2025 adjusted EPS between $15.25 and $16.25, compared to the consensus expectation of $16.24. Meanwhile, total revenue expected to decline by a mid-single digit percentage compared to 2024. This guidance reflects continued pressure on Biogen (NASDAQ:BIIB)’s multiple sclerosis franchise, which is only partially offset by growth from new product launches.
"We believe 2024 was an important year on our journey to deliver long-term sustainable growth," said Christopher A. Viehbacher, President and CEO of Biogen. "We delivered continued revenue growth from our ongoing product launches including LEQEMBI, where we believe there remains a significant long-term opportunity."
For Q4, Biogen reported global LEQEMBI sales of approximately $87 million, with U.S. sales reaching about $50 million. The company’s rare disease portfolio also showed strength, with SKYCLARYS revenue hitting approximately $102 million in the quarter.